Patients & Community The patient perspective is crucial to our success

Living with Inherited retinal disease - Maartje de Kok and her family

ProQR is dedicated to developing RNA therapies to improve the lives of patients, families and communities living with inherited retinal diseases, a group of rare diseases causing blindness. To achieve this goal, ProQR strives to integrate the patient voice into our decision-making throughout the drug development process as we believe that a patient-focused strategy is crucial to our success.

Our patient-focused approach

  • We are committed to the communities we serve.
  • We value patients as experts and strive to integrate their insights into our decision-making.
  • We act with a sense of urgency and purpose in the interest of patients.
  • We believe in early, consistent and transparent engagement with the patient community. 

If you have questions or want to stay informed please contact patientinfo@proqr.com or sign up for our Eye Connect newsletter.

ProQR clinical trials for inherited retinal diseases

Here is a list of all our ongoing clinical trials.
If you are not sure what a clinical trial is all about? Read this first.

Illuminate

Phase 2/3 clinical trial of sepofarsen for CEP290 mediated Leber congenital amaurosis (LCA10).

Read about the Illuminate trial

Illuminate logomark

Stellar

Phase 1/2 clinical trial of QR-421a for USH2A mediated retinitis pigmentosa and Usher syndrome.

Read about the Stellar trial

Stellar logomark

Aurora

Phase 1/2 clinical trial of QR-1123 for RHO mediated retinitis pigmentosa.

Read about the Aurora trial

Aurora logomark

How does RNA therapy work?

Learn how the latest RNA technologies can help treat rare genetic diseases